Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting Summary-Reference-Cited by-同舟云学术

Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting Summary

Published:2021-09 Issue: Volume:155 Page:165-171
ISSN:0090-4295
Container-title:Urology
language:en
Short-container-title:Urology

Author:

Hofmann Martin R.,Hussain Maha,Dehm Scott M.,Beltran Himisha,Wyatt Alexander W.,Halabi Susan,Sweeney Christopher,Scher Howard I.,Ryan Charles J.,Feng Felix Y.,Attard Gerhardt,Klein Eric,Miyahira Andrea K.,Soule Howard R.,Sharifi Nima

Funder

Prostate Cancer Foundation

Publisher

Elsevier BV

Subject

Urology

Reference50 articles.

1. Trends in United States prostate cancer incidence rates by age and stage, 1995-2012;Hoffman;Cancer Epidemiol Biomarkers Prev,2016

2. Increasing incidence of metastatic prostate cancer in the United States (2004-2013);Weiner;Prostate Cancer Prostatic Dis,2016

3. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer;Sweeney;N Engl J Med,2015

4. Enzalutamide with standard first-line therapy in metastatic prostate cancer;Davis;N Engl J Med,2019

5. Apalutamide for metastatic, castration-sensitive prostate cancer;Chi;N Engl J Med,2019

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HSD3B1 genotype and outcomes in metastatic hormone-sensitive prostate cancer with androgen deprivation therapy and enzalutamide: ARCHES;Cell Reports Medicine;2024-08

2. Racial Disparities in Diagnosis and Treatment of Depression Associated with Androgen Deprivation Therapy for Prostate Cancer;Urology;2024-04

3. Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS Study;European Urology;2024-04

4. Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022;European Journal of Cancer;2023-05

5. Prostate Cancer—PET Imaging Update;Cancers;2023-01-28